Clinical research

Retatrutide (TRIUMPH programme): Retatrutide phase 3 results

Released: · Last reviewed: · By Dr. Parmis

Phase 3 programme; the published phase 2 trial was randomised, double-blind and placebo-controlled. Sample size not extracted, over an unspecified duration. Sponsor: Eli Lilly and Company.

Retatrutide (TRIUMPH programme) (no registry ID on file) tested retatrutide, a glp-1, gip and glucagon triple receptor agonist against a comparator in adults with obesity, or overweight with weight-related complications. Unverified — no source on file: the source is a citable record we could not authoritatively link, which we have not independently re-extracted from the full paper in this session.

Study design

DesignPhase 3 programme; the published phase 2 trial was randomised, double-blind and placebo-controlled
PopulationAdults with obesity, or overweight with weight-related complications
Sample sizeNot stated
InterventionRetatrutide, a GLP-1, GIP and glucagon triple receptor agonist
ComparatorNot stated
DurationNot stated
Primary endpointNot stated
SponsorEli Lilly and Company

Results

Not extracted.

Adverse events & discontinuations

Not extracted from the source in this session.

Limitations

Retatrutide is investigational. It is not approved by the FDA or EMA for any indication, and it is not legally available from any telehealth provider or compounder.

Practical interpretation

This is one trial, reported by Eli Lilly and Company, read directly against the registry and publication linked below — GLP Ranked has not re-run the statistics or obtained the patient-level data. Results describe group averages under trial conditions and may not describe any individual's outcome, including with a compounded, non-FDA-approved version of a similar active ingredient. Always check the primary source before citing a specific number.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Sources

  1. Phase 2 results: New England Journal of Medicine, 2023 (source URL not published — treat as unverified) — Peer-reviewed publication
  2. Retatrutide (TRIUMPH programme) — ClinicalTrials.gov search (no direct NCT on file) — Trial registry search
  3. Retatrutide (TRIUMPH programme) — publication DOI 10.1056/NEJMoa2301972 — Peer-reviewed publication (DOI)
  4. PubMed search: Retatrutide (TRIUMPH programme) — Literature database search, checked November 21, 2026
  5. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (retatrutide cannot be compounded) — Regulator page, content current October 1, 2026

Cite this page

GLP Ranked. "Retatrutide (TRIUMPH programme): Retatrutide phase 3 results." https://glpranked.com/research/retatrutide-phase-3/

GLP Ranked. "Retatrutide (TRIUMPH programme): Retatrutide phase 3 results." https://glpranked.com/research/retatrutide-phase-3/